Discovery of a Novel Ubenimex Derivative as a First-in-Class Dual CD13/Proteasome Inhibitor for the Treatment of Cancer
Molecules · 2023
DOI: 10.3390/molecules28176343 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2023. Verfasst von Jian Zhang und 12 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Weifang Medical University, Weifang 261053, China. Hauptthemen laut MEDLINE: Proteasome Inhibitors, Multiple Myeloma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Shandong Province, The Marine S&T Fund of Shandong Province for Pilot National Laboratory for Marine Science and Technology (Qingdao).
Abstract (Originalsprache)
The CD13 inhibitor ubenimex is used as an adjuvant drug with chemotherapy for the treatment of cancer due to its function as an immunoenhancer, but it has limitations in its cytotoxic efficacy. The proteasome inhibitor ixazomib is a landmark drug in the treatment of multiple myeloma with a high anti-cancer activity. Herein, we conjugated the pharmacophore of ubenimex and the boric acid of ixazomib to obtain a dual CD13 and proteasome inhibitor 7 (BC-05). BC-05 exhibited potent inhibitory activity on both human CD13 (IC50 = 0.13 μM) and the 20S proteasome (IC50 = 1.39 μM). Although BC-05 displayed lower anti-proliferative activity than that of ixazomib in vitro, an advantage was established in the in vivo anti-cancer efficacy and prolongation of survival time, which may be due to its anti-metastatic and immune-stimulating activity. A pharmacokinetic study revealed that BC-05 is a potentially orally active agent with an F% value of 24.9%. Moreover, BC-05 showed more favorable safety profiles than those of ixazomib in preliminary toxicity studies. Overall, the results indicate that BC-05 is a promising drug candidate for the treatment of multiple myeloma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, Weifang Medical University, Weifang 261053, China.
- Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, 5 Yushan Road, Qingdao 266003, China.
- Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin 300070, China.
- Marine Biomedical Research Institute of Qingdao, Qingdao 266071, China.
- Laboratory for Marine Drugs and Bioproducts, Qingdao National Laboratory for Marine Science and Technology, Qingdao 266237, China.
ORCID-Profile: Dexin Kong, Xiaoyang Li, Yuqi Jiang
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province
- The Marine S&T Fund of Shandong Province for Pilot National Laboratory for Marine Science and Technology (Qingdao)
- The Taishan Scholars Program
- The Key research and development program of Shandong province
- Marine S&T Fund of Shandong Province for Pilot National Laboratory for Marine Science and Technology (Qingdao)
- Taishan Scholars Program
- Key Research And Development Program of Shandong province
Zitieren
APA
Zhang, J., Sun, S., Liu, J., Zhang, L., Guo, D., Zhang, N., Zhao, J., Kong, D., Xu, T., Wang, X., Xu, W., Li, X., & Jiang, Y. (2023). Discovery of a Novel Ubenimex Derivative as a First-in-Class Dual CD13/Proteasome Inhibitor for the Treatment of Cancer. Molecules. https://doi.org/10.3390/molecules28176343
Vancouver
Zhang J, Sun S, Liu J, Zhang L, Guo D, Zhang N, et al. Discovery of a Novel Ubenimex Derivative as a First-in-Class Dual CD13/Proteasome Inhibitor for the Treatment of Cancer. Molecules. 2023. doi:10.3390/molecules28176343
BibTeX
@article{Zhang2023,
author = {Zhang, Jian and Sun, Simin and Liu, Jinyu and Zhang, Liang and Guo, Di and Zhang, Naixin and Zhao, Jun and Kong, Dexin and Xu, Tongqiang and Wang, Xuejian and Xu, Wenfang and Li, Xiaoyang and Jiang, Yuqi},
title = {Discovery of a Novel Ubenimex Derivative as a First-in-Class Dual CD13/Proteasome Inhibitor for the Treatment of Cancer},
journal = {Molecules},
year = {2023},
doi = {10.3390/molecules28176343}
}
EUVIMED